Pathology Reports: Understanding Your Results

A pathology report is the formal document a licensed pathologist produces after examining tissue or cell samples collected during a biopsy, surgical procedure, or other specimen collection. These reports serve as the diagnostic foundation for cancer care decisions, including treatment planning, staging, and prognosis. Understanding the structure and terminology of a pathology report helps patients and care teams ask precise questions and make informed decisions at each stage of care.

Definition and scope

A pathology report documents the microscopic and macroscopic findings from a tissue specimen submitted to a pathology laboratory. The College of American Pathologists (CAP), through its CAP Cancer Protocols, sets the standardized reporting templates used across accredited laboratories in the United States. These protocols define required data elements for more than 70 cancer types, ensuring that reports contain the minimum diagnostic information needed for staging under systems such as the American Joint Committee on Cancer (AJCC) TNM framework.

The scope of a pathology report varies by specimen type. A core needle biopsy report for a breast mass will contain different elements than a surgical resection specimen from a colorectal tumor. Reports may be preliminary (issued before all staining or molecular testing is complete) or final (incorporating all results). Final reports are the authoritative diagnostic documents used in multidisciplinary tumor board discussions and treatment decisions.

The broader regulatory context for oncology includes laboratory oversight under the Clinical Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare and Medicaid Services (CMS). CLIA certification requires laboratories performing high-complexity testing — the category covering most histopathologic and molecular analyses — to meet quality standards for personnel, proficiency testing, and quality control (CMS CLIA Program).

How it works

The pathology reporting process follows a defined sequence from specimen receipt to final diagnosis.

  1. Specimen accessioning — The laboratory assigns a unique accession number to the submitted tissue, logs the specimen source, collection date, and clinical history provided by the submitting clinician.
  2. Gross examination — A pathologist or pathologist assistant describes the specimen's external appearance: dimensions in millimeters or centimeters, color, consistency, and orientation markers placed by the surgeon.
  3. Tissue processing and sectioning — Specimens are fixed (typically in 10% neutral buffered formalin), embedded in paraffin wax, and cut into sections approximately 4 to 5 micrometers thick for mounting on glass slides.
  4. Hematoxylin and eosin (H&E) staining — The primary stain allowing pathologists to visualize cell morphology, nuclear features, and tissue architecture under light microscopy.
  5. Ancillary testing — Depending on findings, additional tests such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), or molecular profiling and biomarker analysis may be ordered. These tests can identify receptor status, gene amplifications, or mutation profiles that directly inform targeted therapy eligibility.
  6. Diagnosis and report generation — The pathologist synthesizes all findings into a structured report, including a final diagnosis line, synoptic (checklist-style) summary, and narrative microscopic description.

The synoptic summary, required by CAP protocols for resection specimens, provides discrete data fields — such as tumor size, histologic grade, margin status, and lymph node involvement — that feed directly into AJCC staging calculations used across cancer staging and grading.

Common scenarios

Benign versus malignant determination — A report may conclude that a lesion is benign (non-cancerous), malignant, or indeterminate. The distinction between benign and malignant tumors hinges on specific histologic criteria including invasion of surrounding tissue and cytologic atypia.

Margin status reporting — For surgical resections, margin status is critical. A positive margin (tumor cells at the inked edge of the specimen) indicates residual disease may remain. Margins are reported as positive, close (typically defined as tumor within 1 mm of the margin in many protocols), or negative (clear), with the exact measurement recorded in millimeters.

Lymph node assessment — Sentinel lymph node biopsy reports specify the number of nodes examined and the number containing metastatic deposits. For breast cancer sentinel node procedures, isolated tumor cells (≤0.2 mm), micrometastases (0.2 mm to 2 mm), and macrometastases (>2 mm) are reported as distinct categories under AJCC criteria, each carrying different staging implications.

Hormone receptor and HER2 status — Breast cancer pathology reports include estrogen receptor (ER), progesterone receptor (PR), and HER2 status, determined by IHC and confirmed by FISH when IHC results are equivocal (a 2+ IHC score triggers reflex FISH testing per ASCO/CAP guidelines on HER2 testing).

Hematologic malignancies — Bone marrow biopsy reports for conditions such as leukemia or lymphoma incorporate flow cytometry results, cytogenetics, and blast percentage counts alongside morphologic findings.

Decision boundaries

Pathology reports directly determine eligibility thresholds for treatment pathways. A tumor graded as Gleason score 7 (3+4) versus 7 (4+3) for prostate cancer carries different risk stratification under the National Comprehensive Cancer Network (NCCN) risk grouping system, potentially affecting the choice between active surveillance, radiation, and surgery.

When a report contains indeterminate findings — such as a follicular lesion of undetermined significance on thyroid fine-needle aspiration (classified under the Bethesda System for Reporting Thyroid Cytopathology, developed with support from the National Cancer Institute) — clinical teams must weigh the 10–30% malignancy risk range associated with that category against repeat biopsy or surgical options.

Discrepancies between imaging findings and pathology results are a recognized decision point. A radiologically suspicious lesion paired with a benign pathology result may warrant a second opinion on the pathology diagnosis, particularly when the tissue sample may be non-representative. The oncologyauthority.com home resource provides orientation to the full scope of diagnostic and treatment topics covered across the oncology continuum.

Pathologists also flag cases for molecular tumor board review when standard histology is insufficient to determine primary site or when actionable mutations — such as NTRK fusions, MSI-H status, or TMB-H measurements — are identified that may qualify patients for tumor-agnostic therapies approved by the FDA.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)